Canada markets closed

Takeda Pharmaceutical Company Limited (TAK)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
14.84+0.03 (+0.20%)
At close: 04:00PM EST
14.79 -0.05 (-0.34%)
After hours: 05:16PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close14.81
Open14.81
Bid14.55 x 3200
Ask14.85 x 4000
Day's Range14.78 - 14.88
52 Week Range13.19 - 17.15
Volume1,164,281
Avg. Volume1,947,104
Market Cap46.812B
Beta (5Y Monthly)0.54
PE Ratio (TTM)40.11
EPS (TTM)0.37
Earnings DateN/A
Forward Dividend & Yield0.64 (4.31%)
Ex-Dividend DateSept 28, 2023
1y Target Est17.20
  • PR Newswire

    Takeda Accelerates Access to its Dengue Vaccine Through 'Make in India' Manufacturing Partnership with Biological E.

    Takeda (TSE:4502/NYSE:TAK) today announced a strategic partnership with Biological E. Limited, a leading vaccines and biologics company in India, to manufacture Takeda's dengue vaccine, TAK-003. The partnership marks a crucial step in the fight against the global public health threat of dengue fever, aligning with the disease-specific target set by the World Health Organization (WHO) to achieve zero case-fatality rate due to dengue by 2030[i].

  • Business Wire

    Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas

    CAMBRIDGE, Mass. & HYDERABAD, India, February 27, 2024--Takeda (TSE:4502/NYSE:TAK) and Biological E. Limited (BE), a leading India-based Vaccines and Pharmaceutical Company, today announced a strategic partnership to accelerate access to QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) multi-dose vials (MDVs). These doses will ultimately be made available for procurement by governments in endemic countries by 2030 at the latest to support National Immunization Programs. MDVs of

  • CNW Group

    Championing Rare Voices on Rare Disease Day

    February 29th marks Rare Disease Day. On the rarest day of the year, we are reminded of the reality that 1 in 12 Canadians will be impacted by rare disease in their lifetime.1 A critical need exists to create meaningful change and action for the growing rare disease community in Canada.